See more : Ion Exchange (India) Limited (IONEXCHANG.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Galecto, Inc. (GLTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galecto, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vine Hill Capital Investment Corp. Unit (VCICU) Income Statement Analysis – Financial Results
- Star Minerals Limited (SMS.AX) Income Statement Analysis – Financial Results
- Triton Development S.A. (TRI.WA) Income Statement Analysis – Financial Results
- Trimol Group, Inc. (TMOL) Income Statement Analysis – Financial Results
- Garware Technical Fibres Limited (GARFIBRES.BO) Income Statement Analysis – Financial Results
Galecto, Inc. (GLTO)
About Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 830.00K | 490.00K | 441.00K | 188.00K | 111.00K | 0.00 |
| Gross Profit | -830.00K | -490.00K | -441.00K | -188.00K | -111.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.77M | 48.21M | 38.49M | 24.63M | 36.53M | 10.09M |
| General & Administrative | 12.69M | 13.00M | 13.74M | 9.01M | 2.45M | 2.81M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.69M | 13.00M | 13.74M | 9.01M | 2.45M | 2.81M |
| Other Expenses | 3.45M | 0.00 | 0.00 | 0.00 | 1.91M | -479.00K |
| Operating Expenses | 35.63M | 61.21M | 52.23M | 33.64M | 38.97M | 12.91M |
| Cost & Expenses | 36.46M | 61.21M | 52.23M | 33.64M | 38.97M | 12.91M |
| Interest Income | 1.69M | 722.00K | 156.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 417.00K | 0.00 | 0.00 | 0.00 | 2.97M |
| Depreciation & Amortization | 830.00K | 490.00K | 441.00K | 188.00K | 111.00K | 12.91K |
| EBITDA | -37.52M | -61.13M | -51.31M | -34.65M | -36.40M | -12.90M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -39.91M | -61.21M | -52.23M | -33.64M | -38.97M | -12.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.56M | -417.00K | 475.00K | -1.20M | 2.46M | -2.96M |
| Income Before Tax | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M | -15.87M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 417.00K | -475.00K | 1.20M | 1.91M | 2.48M |
| Net Income | -38.35M | -62.04M | -51.28M | -36.04M | -38.42M | -15.87M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -36.08 | -61.04 | -50.75 | -35.66 | -37.76 | -4.42 |
| EPS Diluted | -36.08 | -61.04 | -50.75 | -35.66 | -37.76 | -4.42 |
| Weighted Avg Shares Out | 1.06M | 1.02M | 1.01M | 1.01M | 1.02M | 1.02M |
| Weighted Avg Shares Out (Dil) | 1.06M | 1.02M | 1.01M | 1.01M | 1.02M | 1.02M |
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three weeks Partial response seen in three of five patients with advanced non-small cell lung cancer...
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status...
Galecto Biotech Collapse: Opportunity For Galectin Therapeutics
Galecto Biotech's stock has plummeted 75% due to increased rates of adverse events in its idiopathic pulmonary fibrosis (IPF) trial. Galecto's synthetic, small molecule approach to galectin-3 inhibition may be causing poor tolerability and negative clinical outcomes. Galectin Therapeutics' belapectin,...
Galecto to Present at Investor Conferences in September
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President...
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.
Galecto shares drop 65% as biotech halts development of lung-disease treatment
Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for idiopathic pulmonary fibrosis, a chronic lung disease. After the treatment, GB0139, failed to meet its primary trial...
Galecto to discontinue development of lung disease treatment
Drug developer Galecto said on Tuesday it will discontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study.
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseases Announces next steps for clinical development plan in severe liver diseases
Galecto Reports Second Quarter Operating and Financial Results
BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for...
ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc
On July 25, 2023, ORBIMED ADVISORS LLC (Trades, Portfolio), a renowned investment firm, reduced its stake in Galecto Inc, a clinical-stage biotechnology company based in Denmark. This article provides an in-depth analysis of the transaction, the profiles of both ORBIMED...
Source: https://incomestatements.info
Category: Stock Reports